Receptor tyrosine kinase (RTK)-mediated hyperactivation of the MAPK/Erk pathway is responsible for a large number of pathogenic outcomes including many cancers. Considerable effort has been directed at targeting this pathway with varying degrees of long term therapeutic success. Under non-stimulated conditions Erk is bound to the adaptor protein Shc preventing aberrant signalling by sequestering Erk from activation by Mek. Activated RTK recruits Shc, via its phosphotyrosine binding (PTB) domain (Shc PTB ), precipitating the release of Erk to engage in a signalling response. Here we describe a novel approach to inhibition of MAP kinase signal transduction through attempting to preserve the Shc-Erk complex under conditions of activated receptor. A library of existing drug molecules was computationally screened for hits that would bind to the Shc PTB and block its interaction with the RTKs EGFR and ErbB2. The primary hit from the screen was indomethacin, a non-steroidal anti-inflammatory drug. Validation of this molecule in vitro and in cellular efficacy studies in cancer cells provides proof of principle of the approach to pathway down-regulation and a potential optimizable lead compound.
Introduction
Receptor tyrosine kinase (RTK) signalling is initiated by the binding of an extracellular growth factor. Through a variety of RTK-related idiosyncratic mechanisms, this event results in up-regulation of kinase activity, auto-phosphorylation and recruitment of downstream effector proteins to phosphorylated tyrosine residues. In normal differentiated tissue, cells are not persistently exposed to activating concentrations of growth factors. As a result there is the potential for redundancy of RTKs and their associated downstream signalling proteins. Despite this these proteins are maintained at relatively high concentration in the plasma membrane and cytoplasm respectively. To prevent aberrant signal transduction by the available signalling molecules the cell has to impose rigorous control mechanisms. One such mechanism requires the sequestering of a key member of the mitogen-activated kinase (MAPK) signalling pathway, Erk (extracellular-regulated kinase), by the adaptor protein Shc (Src homology 2-containing transforming protein). As part of this complex Erk is prevented from being recruited to its upstream activating kinase Mek (MAPK/Erk kinase), thus ensuring signal transduction is abrogated in the absence of stimulation [1] .
Shc is an adaptor protein which, despite possessing no intrinsic catalytic activity, plays an integral part in signal transduction pathways that are perturbed in several different cancers [2, 3] . The p52 isoform of Shc (henceforth referred to simply as Shc) comprises an N-terminal phosphotyrosine-binding domain (PTB, henceforth referred to as Shc PTB ), a collagen homology 1 (CH1) domain and a C-terminal Src homology 2 (SH2) domain. In stimulated cells Shc has been shown to play a role in linking RTKs to the MAPK pathway [4] [5] [6] . Post-stimulation phosphorylation of the RTK provides a phosphotyrosine (pY) residue-containing site (bearing the consensus sequence NPXpY, where X is any amino acid [4] ). Shc is recruited to this site through its PTB domain [7] [8] [9] [10] . Subsequent phosphorylation of tyrosine residues (Y239. Y240 and Y317) on the CH1 domain of Shc promotes the recruitment of another adaptor protein, growth factor receptor binding protein (Grb2 [11, 12] ). The concomitant Shc-mediated localization of Grb2 induces complex formation with the guanine nucleotide exchange https://doi.org/10.1016/j.canlet.2019.05.008
factor, Sos, and represents the key initiating event in MAPK signalling. This is followed by up-regulation of Ras and Raf and ultimately results in the phosphorylation of Erk by Mek [13, 14] . The MAPK pathway can also be activated via direct interaction of Grb2 with RTKs followed by recruitment of Sos. Although, this mode of pathway stimulation circumvents Shc mediation, we have previously demonstrated that the sequestration of Erk through binding to Shc was sufficient to inhibit Erk phosphorylation and response [1] .
As the terminal kinase in the MAPK pathway, Erk plays a fundamental role in transducing signals from growth factor-stimulated RTKs to induce cell growth, survival and differentiation. Prolonged phosphorylation of Erk results in cell proliferative signals, as a result Erk is found upregulated in many forms of cancer, including ovarian [15] , prostate [16] and Hodgkin's disease [17] . Activated Erk functions as a serine-threonine kinase directed towards numerous substrate proteins [18] [19] [20] . In its activated state it also translocates to the nucleus to stimulate transcription of specific genes [13, 21] . Erk can also regulate the MAPK pathway through negative feedback inhibition [22] . Furthermore, Erk is involved in cross-talk with other pathways which are usurped in cancer [23, 24] . Erk has two functionally and structurally similar isoforms, Erk1 and Erk2 (henceforth communally referred to as Erk).
Previously we demonstrated that Shc is a key negative regulator of MAPK signalling in non-stimulated cells. Shc forms a complex which sequesters Erk from involvement in MAP kinase signalling [1] . The binding site for Erk is situated on the Shc PTB distal from the pTyr binding site. Recruitment of Shc on RTK up-regulation results in the adaptor protein undergoing a conformational change that releases Erk. Free Erk is then available to be recruited, phosphorylated and hence activated by Mek. In the context of constitutively up-regulated RTKs, the loss of Shc regulation of Erk could be a contributing factor in exacerbating oncogenic phenotypes, thus we reasoned that a molecule that can block Shc binding to activated RTKs without triggering the release of Erk would be beneficial in the treatment of Erk-dependent cancers (Fig. 1A) . Not only would such an inhibitor sustain the Shc-Erk complex, but it is also anticipated that prohibition of Shc PTB binding to the receptor would also prevent phosphorylation of tyrosine residues on the CH1 domain and abrogate the binding of Grb2, hence blocking Ras activation. Thus, discovery of an appropriate molecule will provide a dual function inhibitor. This approach is validated by, for example, the observation that disabling Shc PTB in mice can lead to delayed tumour onset [25] .
Initially an in silico docking screen was used to select small molecule candidates directed at the Shc PTB for the inhibition of Shc-RTKs interaction. Our approach to this was to use an established database of known drug compounds (DrugBank [26] ) to assess whether potential hits could provide an opportunity for repurposing. We discovered that indomethacin, a known non-steroid anti-inflammatory drug (NSAID), interacts with the Shc PTB directly in vitro. We employed biophysical methods and NMR to investigate the interaction at the molecular level and demonstrate that the indomethacin-Shc PTB interaction binds in the canonical phosphotyrosine-binding pocket without disruption of the Erk-binding site. We further show that in cells treated with indomethacin the drug competes with phosphorylated EGFR (epidermal growth factor receptor) for binding to Shc, and in doing so is able to down-regulate Erk signalling in a panel of cancer cell lines. This study provides validation of the approach of inhibiting Shc binding to RTKs as a promising therapeutic strategy as well as highlighting the possibility of developing indomethacin-like compounds as leads to inhibit Erk activity.
Materials and methods

Cheminformatics approach
The chemical structures of the approved drugs were retrieved from the DrugBank database and prepared using the set of programs from OpenEye Software. 
Cell culture
All cells were maintained in Dulbecco's modified Eagle's high glucose medium (DMEM) supplemented with 10% (v/v) foetal bovine serum (FBS) and 1% antibiotic/antimycotic (Lonza) in a humidified incubator with 10% CO 2 .
Reagents
Antibodies for pErk (4695), Erk (4377), pY317 Shc (2431), pY1148 EGFR (4404), EGFR (2646), Tubulin (2144) were obtained from Cell Signalling Technology; Shc (06-203) was from Millipore. Normal mouse IgG (sc-2025), agarose-conjugated Shc antibody (SC-967 AC), agarose-conjugated EGFR antibody (SC-120 AC), and protein A/G plusagarose (sc-2003) were from Santa Cruz Biotechnology. Recombinant Human EGF Protein, CF (236-EG) was from R&D systems. Indomethacin (I7378) was from Sigma-Aldrich, all indomethacin analogues were from ChemBridge Corporation.
Cloning, expression and purification of recombinant proteins
Prokaryotic expression plasmid for Shc PTB domain has been described previously [1] . Shc PTB R175Q was generated using site-direct mutagenesis. Histidine-tagged fusion proteins were purified from BL21(DE3) cells. A single colony was used to transform 100 ml of LB which was grown overnight at 37°C. 1 L of LB were inoculated with 10 mL of this overnight culture and were allowed to grow at 37°C until the OD 600 = 0.8 at which point the culture was cooled down to 20°C and expression was induced with 1 mM IPTG. Cultures were allowed to grow for a further 12 h before harvesting by centrifugation. Cells were re-suspended in 20 mM Tris, 150 mM NaCl, 10% glycerol, pH 8.0 in the presence of protease inhibitors and lysed by sonication. Insoluble material was removed by centrifugation (13,000 g at 4°C for 60 min). The soluble fraction was applied to a Talon column. Following a wash with 10 times column volume of buffer (20 mM Tris, 150 mM NaCl, pH 8.0) protein was eluted from the column with 150 mM imidazole and was concentrated to 5 mL and applied to a Superdex75 gel filtration column in buffer containing 20 mM HEPES, 150 mM NaCl and 1 mM TCEP pH 7.5. Analysis of pure proteins on SDS-PAGE showed greater than 98% purity. . Images were generated using Chimera v. 1.12 [38] and PoseView [39] on line (http://poseview.zbh. uni-hamburg.de/).
Indomethacin treatment and cell lysates
Indomethacin was prepared as 1 M stock in DMSO. For cell based studies, cells were serum starved in the presence of different concentrations of indomethacin overnight. All cells were viable after serum starvation, i.e. we found no evidence of cell death. 10 ng/ml EGF was used to stimulate cells for 2 or 5 min. Following PBS washing, cells were lysed with lysis buffer containing 50 mM HEPES (pH 7.5), 0.1% (v/v) NP-40, 10 mM NaF, 1 mM sodium orthovanadate, 10% (v/v) glycerol, 50 mM NaCl, 1 mM PMSF and Protease Inhibitor Cocktail Set III (Calbiochem) and required concentrations of indomethacin as indicated. Cell debris was removed by centrifugation at 13,000 rpm for 20 min. The detergent soluble fraction was used for western blotting or immuneprecipitation experiments. The cells which are marked as having zero indomethacin have only the experimental level of DMSO added and thus act as a control for the effects of the solvent.
Immunoprecipitation and western blots
For immunoprecipitation experiments, cells were lysed with lysis buffer as described above and 0.5 mg of whole cell lysate was prepared in 500 μL volume. IP antibody was added to the lysate and incubated overnight. The beads were then spun down at 4000 rpm for 3 min, supernatant was removed and the beads were washed with 1 ml lysis buffer. This washing procedure was repeated five times in order to remove non-specific binding. After the last wash, 50 μl of 2× Laemmli sample buffer were added, the sample was boiled and subjected to SDS-PAGE and western blot assay.
For western blotting cells were grown in 10 cm dishes, serum starved overnight and stimulated with 10 ng/ml EGF for the indicated time period. Cells were lysed using lysis buffer as described above. For immunoblotting, proteins were separated by SDS-PAGE, transferred to PVDF membranes and incubated with the specific antibodies. Immune complexes were detected with horseradish peroxidase conjugated secondary antibodies and visualized by enhanced chemiluminescence reagent according to the manufacturer's instructions (Pierce).
Microscale thermophoresis (MST)
The binding affinities were measured using the Monolith NT.115 (NanoTemper Technologies, GmbH). Shc PTB was fluorescently labelled with Atto488 according to the manufacturer's protocol. Labelling efficiency was determined to be 1:1 (protein:dye) by measuring the absorbance at 280 and 488 nm. A 16 step dilution series of the unlabelled binding partner (indomethacin) was prepared in a 2% DMSO solution, mixed with the labelled protein at 1:1 ratio and loaded into capillaries.
Measurements were performed at 25°C in 20 mM HEPES, 150 mM NaCl and 1 mM TCEP pH 7.5 buffer containing 0.01% Tween 20 and 2% DMSO. Data analyses were performed using Nanotemper Analysis software, v.1.2.101, and were plotted using Origin 7.0. All measurements were conducted as triplicates and the errors were presented as the standard error of the triplicates.
Isothermal titration calorimetry (ITC)
ITC experiments were carried out using a MicroCal iTC200 (Malvern) or VT ITC at 25°C. Twenty 15 μl injections of 1400 μM indomethacin were made into 140 μM Shc PTB in the calorimeter cell. Control experiments involving the injection of 1400 μM indomethacin into buffer or buffer into 140 μM Shc PTB were performed. The heat per injection was determined and subtracted from the binding data. Data were analysed using a single independent site model using Origin software.
For the Shc PTB binding to phospho-EGFR and phosphor-ErbB2 peptides experiments, twenty 2 μl injections of 500 μM peptides were titrated into 50 μM Shc PTB . Shc PTB -indomethacin complex was prepared by pre-incubation of 50 μM Shc PTB with 2 mM indomethacin.
Indomethacin was prepared as a 1 M stock solution in 100% DMSO and diluted to desired concentration with 2% DMSO final concentration.
Nuclear magnetic resonance spectroscopy (NMR)
NMR acquisitions were carried out in the NMR buffer (20 
Wound healing assay
A431 cells were serum-starved overnight by which time confluence reached about 80%. An artificial homogenous wound was made onto the monolayer using an IncuCyte ® 96-well WoundMaker Tool. After wounding debris was removed by washing cells with PBS. Serum-depleted medium containing 800 μM of indomethacin or the same volume of DMSO were added to the wounded cells and 100 ng/ml of EGF ligand was added to each well. At different time points cells that migrated into the wounded area or cells with extended protrusions from the wound border were photographed using IncuCyte Live-Cell Analysis.
Results
Identification of small molecules for Shc PTB by in silico docking
We performed an in silico screen of approved drug compounds from the DrugBank database [27] to identify potential hits directed at the pTyr binding site on the Shc PTB . This pocket is highly positively charged to accommodate the tyrosyl phosphate of the cognate RTK. The available structure of pTyr bound to Shc PTB reveals that pTyr is placed the electron-deficient pocket in Shc PTB surrounded by three basic amino acids (Arg67, Arg175 and Lys169) which make strong electrostatic interactions [7] . The computational model was built to capture the same chemical environment to dock the drugs into the PTB domain of Shc (Fig. 1B) . The DrugBank drug compounds were evaluated to attribute charges for the basic and acid groups at neutral pH. Before analysis, fatty acids, amino acids, polycarboxylated compounds and compounds with multiple charges were identified and excluded from the study. Drugs having one carboxylic acid moiety were prioritized in the knowledge that this chemical group is a bioisostere of the phosphate on tyrosylphosphate-containing ligands.
The most promising drug for further studies was selected using an approach comprising the weighted Chemgauss4 score (dividing the score value by the molecular weight of the compound). Bearing in mind that some molecules presented poses with almost no overlap with the native ligand, the intermolecular interactions and pose in comparison with the native ligand were also considered in the analyses. After an analysis of the top scored compounds indomethacin, a known NSAID, was found to be the best virtual hit optimizing interactions with both Arg67 and Lys169 on the Shc PTB structure (Fig. 1C) . Indomethacin sits in the heart of the pTyr binding site with a similar intermolecular interaction pattern that was observed for the native ligand in the target pocket.
Indomethacin binds to the phosphotyrosine-binding pocket of the Shc PTB domain
Both isothermal titration calorimetry (ITC) and microscale thermophoresis (MST) were used to determine the affinity of the interaction between the recombinant Shc Fig. 2A) suggests that the binding of the drug is driven by the change in entropy (ΔS) implicating the release of water molecules from apolar surface in the binding site as an important energetic contribution to interaction. This observation is supported by the presence of Phe202 that, in our docking model, interacts with the hydrophobic surfaces of the indole and chlorobenzoyl groups in indomethacin (Fig. 1C) . We failed to observe binding amongst a range of indomethacin analogues and carboxylic acid-containing compounds suggesting that the pTyrShc PTB binding site exhibits some selectivity for indomethacin ( Supplementary Fig. 1 ).
Having shown that indomethacin and the Shc PTB interact directly, we endeavoured to ascertain whether the interaction between (Fig. 3A and B, Supplementary   Fig. 2 ). As expected for a ligand with moderate affinity the chemical shift changes are not pronounced, however clear shifts are observable for some atoms. Attributing these to residues in the PTB domain and mapping these onto the structure (Fig. 3C) , shows that the region that experiences the largest perturbation includes that proximal to the pTyr binding site incorporating Lys169 which is expected to hydrogen bond with indomethacin (Fig. 1C) . Indeed, the largest shift is seen for Gln148 which points toward the pTyr binding site. Importantly, the binding of indomethacin appears to be located distally from the Erk binding site suggesting that binding of the drug would not impinge on the sequestering of Erk by Shc (Fig. 3C) . 3C and 3D ). It is clear from the plots of CSP derived from these two compounds that the impact on the Shc PTB structure is negligible. This suggests further that within the indomethacin analogues there is selectivity for this site.
To confirm that indomethacin binds in the pTyr binding pocket we mutated an arginine residue in the Shc PTB binding site, which is essential for pTyr recognition, to the polar glutamine (Arg175Gln). The reduction of the affinity by approximately an order of magnitude (K d = 590 ± 54 μM; Fig. 3D ) demonstrates that indomethacin, like the pTyr cognate ligand requires the presence of Arg175. Although Arg175 does not appear to sustain the interaction in the original screening model, this amino acid is placed at 4.2 and 4.4 Å respectively away from the charged groups of indomethacin. This distance falls within the range of a salt bridge interaction and hence could stabilize the positioning of the carboxylic acid group on indomethacin.
Indomethacin competes with RTK for binding of Shc
PTB
The efficacy of indomethacin as an inhibitor of binding of Shc PTB to
RTKs is dependent on its ability to compete for binding to Shc with the tyrosyl phosphate site on the receptor. The Shc PTB has been shown to directly interact with phosphorylated tyrosine residues on the EGFR family RTKs EGFR (aka. ErbB1; human epidermal growth factor receptor binding protein 1) and ErbB2 upon stimulation by EGF [38] [39] [40] . ITC was used to provide a qualitative assessment of whether the binding of cognate pTyr-containing peptides could be inhibited by the presence of indomethacin. Peptides corresponding to the amino acid sequences around pTyr1148 (EGFR peptide: STAVGNPEpYLNT) on EGFR, and pTyr1122 (ErbB2 peptide: SPAFDNLYpYWDQ), a proposed binding site on ErbB2, were synthesized and 500 μM of each was titrated into 50 μM of Shc PTB in the absence, or the presence of 2 mM indomethacin ( Fig. 4A and B). The binding of the Shc PTB to the peptides is low affinity, however the changes in observed heat measured, when compared to the control experiment of buffer into PTB domain, reveal that binding occurs. The isotherms obtained also show that when the Shc PTB is presaturated with indomethacin the binding is reduced or abrogated altogether. Using MST we could measure the binding of Shc PTB to ErbB2 pTyr1122 in the absence and presence of indomethacin. As with the ITC experiment in the absence of the small molecule binding was observed (K d = 261 ± 50.7 nM), however after saturation no binding was apparent (Fig. 4C) .
Indomethacin down-regulates EGF-dependent Erk pathway in cancer cell lines
The in vitro experimental data to date validate the in silico docking model and demonstrate that indomethacin binds with moderate/low affinity and occupies the pTyr-binding site within the Shc PTB . These data also confirm that indomethacin can prevent the recruitment of Shc PTB to activated RTKs, and hence potentially prolong the sequestering of Erk from MAPK signalling. To explore this we used cell-based assays to assess how downstream signalling might be affected by the inhibitory presence of indomethacin. A panel of cell lines which express Shc were serum-starved overnight in the presence of indomethacin at varying concentrations. Cells were then stimulated with 10 ng/ml EGF for 2 min. Amongst the cell lines we chose two breast cancer cell lines, MCF7 and SkBr3, due to the strong link between Shc expression status and breast cancer progression. We also tested carcinoma cell lines derived from skin (A431), kidney (A498) and cervix (HeLa). The effects of indomethacin on EGFR signalling were examined by immunoblotting.
In all cell lines we used, the phosphorylation of Erk upon EGF stimulation was down-regulated upon indomethacin treatment (Fig. 5) . Examination of the signalling events that occur upstream of Erk revealed two discrete mechanisms. In the first mechanism (represented by SkBr3, Fig. 5B and A498, Fig. 5D ) the MAPK pathway is up-regulated on addition of EGF leading to phosphorylation of Mek which is independent of the concentration of indomethacin added. However, the level of pErk is reduced in a dose-dependent way, suggesting that the presence of the drug restricts the availability of Erk to the upstreamactivated pathway. Since the population of pShc does not change in response to indomethacin, it is likely that an ancillary, non-receptor tyrosine kinase is responsible for the phosphorylation of Shc. This kinase is up-regulated by the EGF-activated receptor independent of Shc recruitment, but is able to phosphorylate Y317 and hence effect the recruitment of Grb2 to initiate MAPK signalling. A prime candidate for this kinase is Src which has been previously shown to bind to, and phosphorylate Shc on receptor stimulation [41, 42] and is known to be expressed in both SkBr3 and A498 cells. Indeed, Shc PTB -independent interactions activate Src family kinases in a subset of breast cancers [43] . In the second mechanism (MCF7, Fig. 5A ; A431, Fig. 5C ; and HeLa, Fig. 5E ) the levels of phosphorylation of all of the components of the MAPK pathway (i.e. Shc, Mek and Erk) are depleted in an indomethacin dose-dependent manner suggesting that the inhibitor is blocking binding to the receptor in a conventional way. For example, in HeLa cells there is a clear correlation in reduction of pShc and pErk. The concomitant reduction in pMek confirms that the entire MAPK pathway is being inhibited. The lack of prolonged elevation of pShc indicates that there is no impact from ancillary kinase activity. The question as to why the different mechanisms prevail in cell lines is likely to be the result of differential protein expression profiles in the cells. In particular, the availability of active non-receptor tyrosine kinase in some cell lines can impact on Shc phosphorylation and drive the MAPK pathway through recruitment of Grb2. However, in all cases the sequestering of Erk from the pathway down-regulates downstream signalling.
Our binding studies indicate that the affinity of indomethacin for (C) Chemical shift perturbations of residues (> 0.03 ppm) from plot in (B) mapped on the NMR structure of the Shc PTB (PDB code: 1SHC). The colour gradient from salmon pink to red indicates the strength of the perturbation (ppm) of specific residues. The critical residues in the pTyr binding pockets are coloured in yellow (R67, K169, and R175). The image shows that putative binding region with localized higher perturbation is proximal to the pTyr binding pocket. 
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the PTB domain is significantly tighter than the effective concentration of indomethacin used in cancer cell lines. This common observation in inhibitor studies could result from several sources. For example, the ability of indomethacin to penetrate different cell membranes and the stability of indomethacin once inside the cell.
Indomethacin competes with EGFR for binding to Shc in cancer cell lines
Finally, having shown that indomethacin inhibits the binding between Shc and EGFR in vitro and EGFR-dependent Erk phosphorylation in different cancer cell lines, we sought to establish that the Shc-EGFR interaction is indeed disrupted upon indomethacin treatment. We immunoprecipitated Shc from MCF7, Fig. 6A (Fig. 6F) . The Shc-mediated complex formation was examined by immunoblotting. Treating cells with indomethacin is shown to apparently block the EGFR-Shc interaction upon EGF stimulation (Fig.s 6A-F) . This confirms that indomethacin can compete with the pTyr residues on EGFR for binding to Shc PTB .
One outcome of EGFR-mediated MAPK pathway activation is increased cell motility. Therefore, to confirm the role of indomethacin in the inhibition of Shc-mediated MAPK signalling, we performed a wound-healing assay using A431 cells. Serum-starved A431 cells were stimulated with 100 ng/ml EGF in the presence of 800 μM of indomethacin or the same volume of DMSO (Fig. 6G) . The assay clearly demonstrated that the indomethacin treatment inhibits the migratory potential of A431 cells over the time course.
Discussion
The MAPK pathway is a key regulator of several important cellular functions such as proliferation, survival and migration. Dysregulation of its upstream components such as RTKs and the small GTPase, Ras is the driver for a range of pathologies including cancer. Numerous studies have focused on exploring the mechanisms of activation of MAPK signalling and regulation to provide therapeutic approaches to block oncogenic signal transduction. Here, we sought a fundamentally novel approach to downregulate MAPK signalling through inhibition of Shc-mediated activity of Erk by identifying a small molecule inhibitor for the Shc PTB -EGFR interaction. In preventing Shc from binding to activated EGFR, the small molecule can have dual functionality through contributing to reduction of pErk by two distinct mechanisms; 1) stabilising the Shc-Erk complex, and 2) preventing phosphorylation of Shc by the receptor and thus blocking the recruitment of Grb2. In silico docking studies directed at Shc PTB revealed a known NSAID, indomethacin, as the best virtual hit. In vitro biophysical binding assays confirmed that indomethacin can interact with Shc PTB . NMR spectroscopic analysis indicates that the binding site for indomethacin on PTB is located within the pTyr-binding pocket. Importantly, we did not observe any significant chemical shifts at the Erk binding interface upon indomethacin binding (Fig. 3C) [1] . This indicates that binding indomethacin can block the interaction with the receptor without perturbation of the interaction with Erk. To test our observation in a cellular context, we treated several cancer cell lines with indomethacin and examined its effects on MAPK signal transduction. Evidence of a reduction of pErk was observed which appears to be driven in specific cell types by two distinct mechanisms of a dual function inhibitor.
While indomethacin is commonly used as an anti-inflammatory drug through inhibiting the cyclooxygenases Cox-1 and -2, it has been reported to show some cancer suppressive activities. Inhibition of Cox-2 was revealed to be effective in blocking angiogenesis in tumours, and prodrugs incorporating indomethacin have been used to target cancer cells and block vascular development [44] . Indomethacin has also been shown to reduce cell migration [45] and invasion [46, 47] , properties associated with cancer progression. Indeed indomethacin appears to be able to interfere with calcium-dependent pathways and focal complexes, which in turn, contribute to blocking cancer cell migration. Furthermore, a number of studies have shown that indomethacin inhibits cell proliferation and augments apoptosis in colorectal cancer cell lines, some of which do not express Cox-1 or -2 [48] . This indicates that such anti-tumour effects are mediated in a Cox-independent manner, at least in some cellular environments. Through our interdisciplinary approach, we have demonstrated that indomethacin competes with activated EGFR for the pTyr-binding pocket in the Shc PTB and in doing so is able to reduce the levels of free Erk leading to depression of MAPK signalling. In this way indomethacin can negatively impact on proliferative outcomes from cells in tumour growth. Interestingly, EGF is a known potent activator of Cox-2 [49] , therefore the role of indomethacin highlighted here might also extend to down-regulation of the tumour-associated activity of this protein.
The PTB domain from Shc has been shown to bind to other ligands that can impinge on cancer signalling. One important example is the phosphatase PTP-PEST which is a known binding partner of Shc PTB [50] . Depletion of PTP-PEST in triple negative breast cancer cells leads to hyperactivation of Erk, and its over-expression results in dephosphorylation of EGFR and Shc at Y317 [51] . However, the impact of this negative-regulator of MAPK signalling is likely to be offset in the treatment with high doses of indomethacin. Our data show that at high dosage indomethacin can inhibit the EFGR-Shc PTB interaction which we have shown is of the order of 100 nM. Since the interaction between PTP-PEST is of the order of 10 μM [52] it is likely that the drug would block this interaction at similar dosage. It is thus clear that in some cell lines the effect of indomethacin in inhibition of negative regulators of proliferative signalling would need to be weighed against the modus operandi described herein. Indomethacin binds at least 100-fold weaker than a pTyr-containing peptide corresponding to the cognate binding site for Shc on EGFR. This makes it unsuitable as a drug for targeting Shc. Nonetheless, our data provide strong validation for an approach that targets the Shc PTB and the resulting sequestering of Erk. It may also suggest the potential for development of indomethacin as a hit compound toward lead generation.
Fig. 6. Indomethacin competes with EGFR for binding to Shc. (A) MCF7, (B)
SkBr3, (C) A431, (D) A498, and (E) HeLa cells were used to immunoprecipitate Shc and observe the Shc-EGFR complex formation by immunoblotting. Cells were serum-starved and treated with indomethacin (MCF7: 0 μM and 800 μM, SKBR3: 0 μM and 800 μM, A431: 0 μM and 800 μM, A498: 0 μM and 1600 μM, and Hela: 0 μM and 800 μM). After EGFR stimulation cells were lysed and probed for Shc and EGFR, (F) A431 cells were use to immunoprecipitate EGFR and observe the EGFR-Shc complex formation by immunoblotting, and (G) Representative images and quantitative data of a wound healing migration assay in the presence or absence of 800 μM indomethacin for 16 and 20 h.
